Abstract: Multiple myeloma (MM) is a hematologic malignancy caused by the malignant proliferation of plasma cells in bone marrow. Currently, chemotherapy, autologous stem cell transplantation, proteasome inhibitors, immunoregulatory drugs, and monoclonal antibodies are used to treat MM in clinical practice, but MM eventually relapses and becomes incurable. The treatment of relapsed/refractory MM (R/R MM) continues to be a difficult challenge. In recent years, with the development of the chimeric antigen receptor T cell (CAR-T) technology, anti-BCMA CAR-T therapy has shown a high response rate and high efficacy in clinical trials as a novel method for the treatment of R/R MM. Herein, we summarize the latest experimental results and prospects of the existing anti-BCMA CAR-T products.